Not all patients are candidates for targeted therapies. The suitability of these treatments often depends on the specific genetic markers and molecular characteristics of the tumor. Diagnostic tests such as biopsies and genetic sequencing are typically performed to identify these markers. For instance, PARP inhibitors are often used in patients with BRCA1 or BRCA2 mutations.
